DNA REPAIR INHIBITORS: WHAT’S ‘ENOUGH’ INHIBITION?

There is increasing interest in agents theoretically capable of inhibiting human DNA repair pathways. Clinical trial design must address their most effective mode of deployment. In this section, we use two therapeutic examples to demonstrate the two roles of DNA repair inhibitors in cancer therapy.